ResMed (ASX:RMD) share price on watch after beating expectations in FY21

This sleep treatment company was on form again in FY 2021…

| More on:
A man wakes up happy with a smile on his face and arms outstretched.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc (ASX: RMD) share price will be one to watch this morning.

This follows the release of the sleep treatment focused medical device company's full year results.

ResMed share price on watch after beating expectations

  • Revenue increased 8% to US$3.2 billion
  • Non-GAAP operating profit up 12% to US$993.8 million
  • Non-GAAP net income rose 13% to US$780.6 million
  • Earnings per share increased 12% to US$5.33

What happened in FY21 for ResMed?

ResMed was a positive performer in the fourth quarter, outperforming the market's expectations for both revenue and earnings per share. This could bode well for the ResMed share price today.

Pleasingly, it was the same story for the whole of FY 2021, with ResMed delivering solid revenue and profit growth despite cycling a period boosted by COVID-19 ventilator sales.

The company notes that it derived incremental respiratory care revenue from COVID-19 related demand of approximately US$20 million in the fourth quarter. This compares to US$125 million in the prior corresponding period.

ResMed was able to offset this with strong sales from its core business thanks to a recovery in its sleep apnoea and COPD patient flow. This was boosted by a major quality issue from one of its leading competitors.

This led to full year Global Device sales rising 7% to US$1,610 million, Mask sales increasing 11% to US$1,213.2 million, and Software as a Service sales growing 5% to US$373.6 million. Growth was delivered both in the United States market and internationally.

What did management say?

ResMed's CEO, Mick Farrell, was pleased with the company's strong finish to the year.

He commented: "Our fourth quarter and full-year fiscal year 2021 results continue to demonstrate the strength and resiliency of our business. During the quarter, we saw the ongoing recovery of core sleep apnea and COPD patient flow across our business, as healthcare systems continue to adopt new models of patient care. We faced some headwinds this quarter, as we annualized the $125 million in COVID-related ventilator sales from this period in 2020, and we saw some tailwinds from a competitor's major quality issue that was announced during the quarter.

"At this time of incredible demand for ResMed products, we are doing everything we can to increase our manufacturing of sleep and respiratory care devices. Our global team is supporting patients, providers, and physicians with our priority to get products directly into the hands of patients who need therapy most."

What's next for ResMed?

While no guidance was given for the year ahead, management spoke positively about its prospects in FY 2022.

Mr Farrell explained: "Looking ahead, we are confident in our ability to grow steadily through our fiscal year 2022 and to deliver for all our stakeholders. We're driving accelerated adoption of digital health solutions in sleep apnea, COPD, and out-of-hospital care, accelerating our ResMed 2025 strategy. These digital health solutions provide efficiency and lower costs for providers and payers, as well as better quality-of-life and clinical outcomes for patients and physicians, and sustainable growth for all of our ResMed stakeholders."

The ResMed share price is up 35% since the start of the year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Earnings Results

Westpac shares on watch amid $6.99b profit and new buyback

Has the big four bank delivered the goods for investors this year? Let's find out.

Read more »

Woman inspecting packages.
Earnings Results

This top 50 ASX stock is diving 5% despite a strong outlook

Investors were looking for more.

Read more »

Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices
Earnings Results

Macquarie share price sinks despite $1.6b half year profit and new buyback

How did this investment bank perform during the first half? Let's find out.

Read more »

A woman holds her hand out under a graphic hologram image of a human brain with brightly lit segments and section points.
Earnings Results

Why the BrainChip share price is in the spotlight this week

Today's reaction is in stark contrast to the day of the release.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

Read more »

A businesswoman ponders why her boat is sinking in the ocean.
Resources Shares

Lake Resources share price sinks on quarterly cash flow news

Let's take a look at the highlights of the company's Q3 update.

Read more »

Lithium ion batteries
Earnings Results

Needs a recharge: Novonix share price sees red after Q3 earnings

Investors were likely expecting a tad more.

Read more »

chip and tech stocks represented by two computer chips side by side
AI Stocks

Up 237% in 2024, why is the Appen share price racing higher again today?

Investors are bidding up Appen shares again today. But why?

Read more »